Table 1.
Summary of CTC cell lines.
| Cell Line | Type of Cancer | Establishing Rate | Culture Period or Passage | Doubling Time | Xenograft | Specific Characteristics | References |
|---|---|---|---|---|---|---|---|
| CTC-1, CTC-2, CTC-3 | Breast cancer | 3/38 | Several passages? | N/A | Yes (all 3 CTC lines) | EpCAM(−) | Zang et al. (2013) [9] |
| BRx33, BRx07, BRx68, BRx50, BRx42, BRx61 | Breast cancer | 6/36. Several cell lines from the same patient at different times | >6–12 months | 3 days to 3 weeks | Yes (3 out of 5 CTC cells lines) | ER(+), PIK3CA, TP53, KRAS, FGFR2 | Yu et al. (2014) [10] |
| MSK-PCa5 | Prostate cancer | 1/17 | Passage was performed weekly at a 1:3 ratio | 1 week | Yes | CK(+), AR(+),High PSA, PTEN(−), RB(−) | Gao et al. (2014) [11] |
| CTC-MCC-41 | Colon cancer | 1/50 (CTC-positive patients) | >16 months | 20 h | Yes | EpCAM(+), Snail, ALDH1, CD133, | Cayrefourcq et al. (2015) [12] |
| BHGc7, BHGc10 | Small cell lung cancer | 2/30 | >4 months. Long-term culture was confirmed by two follow-up studies | N/A | Yes | Carbonic anhydrase (CAIX) | Hamilton et al. (2015) [13], (2016) [14] |
| N/A (one line was named CTC-TJH-01 by Que [20]) | Lung adenocarcinoma | 2/35 | >6 months | N/A | N/A | Wang et al. (2016) [15] | |
| BHGc16, BHGc26, UHGc5 | Small cell lung cancer | N/A | N/A | N/A | N/A | CD133, CD24, SOX-2 | Klameth et al. (2017) [16] |
| CTC44, CTC45 (both established from the same patient) | Colorectal cancer | 3/4. Several cell lines from the same patient at different times | >20 passages | N/A | Yes | CD133, CD26, ALDH1A1, CD44 | Grillet et al. (2017) [17] |
| BRx82, BRx142 | Breast cancer | N/A | N/A | 101.2 and 59.7 h | N/A | Able to cryopreserve | Sandlin et al. (2017) [18] |
| CTC-MCC-41.4, 41.5A. 41.5B. 41.5C, 41.5D. 41.5E, 41.5F, 41.5G (established from the same patient) | Colon cancer | N/A. Several cell lines from the same patient at different times (8 cell lines) | N/A | N/A | N/A | ALDH1, CD44, panCD66, EpCAM | Soler et al. (2018) [19] |
| CTC-TJH-01 | Non-small cell lung cancer | 1/89 | 24 months | N/A | Yes | CXCL5, CD44, ALDH1 | Que et al. (2019) [20] |
| CTC-3 | Breast cancer | 1/16 | >2 years | N/A | Yes | CD44 | Zhao et al. (2019) [21] |
| CTC-ITB-01 | Breast cancer | 1/50 | >4 years | N/A | N/A | E-Cadherin, EpCAM, K19, CD24, Twist 1 | Koch et al. (2020) [22] |
| UWG01CTC, UWG02CTC | Gastroesophageal cancer | 2/23 | >12 months | N/A | Yes | EpCAM(−), CD56, (UWG01CTC) or EpCAM(+), CK(+), CD44, E-Cadherin | Brungs et al. (2020) [23] |
| Mel-167, PEM-22, Mel-182, PEM-78 | Melanoma | 4/37. Several cell lines from the same patient at different times (Mel 182-1, Mel 182-2) | N/A | N/A | Yes | BRAF-mutant NG-2, MLANA | Hong et al. (2021) [24] |
| EMC-Pca-41 | Prostate cancer | 1/40 | >1 year, 10 passages | N/A | N/A | TMPRSS2-ERG fusion, loss of PTEN | Mout et al. (2021) [25] |
N/A: not available.